文献速递结核与非结核分枝杆菌医院感染防控

低流行国家生物制剂治疗患者结核预防:20年专科门诊经验

Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country.
PubMed 文献 · Clin Infect Dis · 2026-01-01

在低流行国家的专科结核门诊中,1368例启动生物制剂(BioT)治疗的患者先后采用4种结核感染筛查策略。随访期间11例(0.8%)发生结核,11年无结核概率99.1%,各筛查时期无显著差异;基线筛查阴性者的结核均发生于BioT暴露第一年内。结论:BioT相关结核可显著减少但无法完全预防,基线筛查阴性后无需双重检测或定期系统复筛。

要点

  • 基线筛查阴性后不推荐定期系统复筛结核感染
  • BioT相关结核不能完全预防,需关注暴露第一年内的风险
  • 单用IGRA(QFT)筛查策略下结核感染诊断比例低于含TST策略

核心结论

  • BioT相关结核可显著减少但无法完全预防;基线筛查阴性后无需双重检测或定期系统复筛。

研究设计与样本

  • 单中心专科结核门诊20年经验分析,共1368例启动生物制剂治疗的患者,按4个连续时期采用4种筛查策略。

主要发现

  • 327例(23.9%)诊断为结核感染,4个时期分别为40.8%、39.5%、25.3%、14.8%(P = .000)。
  • 以第一时期为参照,第二、三、四时期调整OR分别为0.89(95% CI,.55-1.44)、0.49(95% CI,.33-.73)、0.23(95% CI,.15-.36)。
  • 随访中11例(0.8%)发生结核,BioT暴露11年后保持无结核概率为99.1%,各筛查时期无显著差异(P = .372)。
  • 基线筛查阴性者的结核病例均发生在BioT暴露第一年内。

关键数值与推荐

  • 筛查策略4种:两步TST;两步TST加QFT Gold In-Tube;单步TST加QFT Gold In-Tube;单用QFT Gold In-Tube(或QFT Gold Plus)。
  • 所有诊断为结核感染的患者均接受预防性治疗。

临床怎么用

  • 对启动BioT患者进行基线结核感染筛查并按阳性结果给予预防治疗,基线阴性后不安排定期系统复筛。

局限性

  • 单中心专科门诊经验,非随机对照设计,筛查策略按时期划分,结果可能受时期因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study builds on previous evidence to assess the risk of tuberculosis (TB) in patients treated with biologic therapies (BioT), the role of the interferon-γ-release assay (IGRA) QuantiFERON-TB (QFT) Gold as a stand-alone screening test, and whether periodic re-testing is warranted for patients with a negative pre-BioT screening. METHODS: A total of 1368 patients starting BioT were screened for TB infection using 4 screening strategies over 4 consecutive periods: (1) 2-step tuberculin skin test (TST); (2) 2-step TST plus QFT Gold In-Tube; (3) single-step TST plus QFT Gold In-Tube; and (4) QFT Gold In-Tube (or QFT Gold Plus) alone. All patients with TB infection were offered preventive therapy. RESULTS: TB infection was diagnosed in 327 (23.9%) patients (40.8%, 39.5%, 25.3%, and 14.8% in the first, second, third, and fourth periods, respectively; P = .000). The adjusted odds ratios (ORs) with respect to the first period were 0.89 (95% CI, .55-1.44), 0.49 (95% CI, .33-.73), and 0.23 (95% CI, .15-.36) for the second, third, and fourth periods, respectively. During follow-up, 11 patients (0.8%) developed TB. The probability of remaining TB-free after 11 years of BioT exposure was 99.1%, with no significant differences between screening periods (P = .372). All TB cases in patients with negative baseline screening occurred within the first year of BioT exposure. CONCLUSIONS: Although BioT-associated TB can be significantly reduced, it is not completely preventable. Neither dual testing nor periodic systematic re-screening for TB infection is warranted after a negative pre-BioT test.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pérez-Recio S, Grijota-Camino MD, Guardiola J, et al. Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country. Clin Infect Dis. 2026. PMID: 40911528. doi:10.1093/cid/ciaf491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。